At present, it remains unclear exactly how much America’s new 10% tariff on the UK will cost the pharmaceutical industry. What is clear, however, is that these levies include medical products, meaning pharmaceutical businesses can expect to feel the effects. As US tariffs on UK goods come into force, uncertainty has become yet another variable in an already complex operating environment.
For large pharmaceutical businesses, uncertainty translates into one overriding concern: protecting value. In volatile conditions, safeguarding the share price becomes paramount. For organisations looking to preserve profitability amid shifting US tariffs, now is the time to sharpen focus on two tightly connected areas: supplier costs and brand reputation.
This is where Chief Procurement Officers (CPOs) can make a tangible difference. Procurement teams in the pharmaceutical sector manage particularly large and complex supplier networks, largely because clinical development relies heavily on outsourced activity. The more suppliers involved, the greater the exposure to cost overruns, compliance failures, and reputational risk. As a result, CPOs must ensure their teams are equipped to mitigate both financial and non-financial impacts, especially in the context of rising pharmaceutical tariffs.
One of the most effective ways to do this is by strengthening collaboration between procurement and internal operational teams, particularly those working in development operations and clinical science.
Why managing cost and reputation matters more than ever
Before exploring how this collaboration works in practice, it is worth revisiting why managing cost and brand reputation is so critical in the pharmaceutical industry. Brand reputation in this sector is exceptionally fragile. Even minor compliance breaches, including those that occur outside a company’s direct control, can have severe consequences. Ultimately, accountability rests with the sponsor organisation.
This reality was demonstrated in the late 2000s when GSK identified a compliance issue during an audit. The issue arose from social structures in the country of operation rather than from internal misconduct. Despite doing the right thing and self-reporting to regulators, the outcome was significant public scrutiny and brand damage. The lesson was clear: regardless of where an issue originates, responsibility cannot be outsourced.
GSK’s experience is not unique. Many large pharmaceutical companies have faced similar situations, reinforcing a critical takeaway for procurement teams. How a business behaves, and how it is perceived to behave, matters enormously.
Cost management, while traditionally secondary in clinical development, is now moving higher up the agenda. In the classic cost-time-quality triangle, time and quality typically dominate. These priorities are essential for bringing new treatments to market safely and effectively. Cost has historically taken a back seat. However, in an environment shaped by tariff increases, supply chain uncertainty, and geopolitical disruption, this balance must be reassessed.
With US tariffs adding pressure across international supply chains, pharmaceutical businesses must now pay closer attention to supplier costs, without compromising compliance, timelines, or data integrity.
The role of procurement in mitigating risk
So how can CPOs help their organisations keep both costs and reputational exposure within an acceptable range?
The answer lies in deeper, more consistent internal engagement. Procurement teams should work far more closely with colleagues who have deep operational and scientific expertise, particularly within development operations and clinical science functions. These teams possess detailed knowledge of trial design, regulatory requirements, and acceptable cost structures, insight that can materially strengthen procurement decision-making.
In practice, this collaboration can be invaluable. For example, a procurement professional may suspect that spending on medical monitoring for a study is higher than expected but hesitates to challenge costs for fear of affecting data quality or trial integrity. An operational colleague, however, may be able to quickly assess the development plan and budget, identify benchmarks, and confirm whether costs are genuinely justified.
This type of input helps procurement teams challenge suppliers confidently, reduce unnecessary expenditure, and still protect quality and compliance. It also reduces the risk of cost creep, which becomes especially important as tariff increases place additional pressure on budgets.
Breaking down internal silos
To maximise this benefit, collaboration should not be limited to ad hoc conversations. Regular engagement, whether through structured forums or informal co-location, allows procurement teams to absorb technical context, ask better questions, and deepen their understanding of the clinical environment.
Face-to-face interaction, even occasionally, enables procurement professionals to hear how scientists and operations teams discuss challenges, risks, and priorities. Over time, this exposure builds credibility and positions procurement as a knowledgeable partner rather than an administrative function.
Reducing barriers between departments is critical. The more integrated procurement becomes with internal specialists, the more effectively teams can manage supplier performance, reduce compliance risk, and control costs. This integration can be formalised by embedding procurement professionals into study teams, ensuring they are involved early rather than brought in late to negotiate contracts under pressure.
From this position, procurement can actively support brand reputation by ensuring supplier qualification processes are robust, documentation is complete, and compliance expectations are clearly communicated and enforced across the supply base.
Looking ahead
In a climate shaped by US tariffs on UK goods, CPOs have an opportunity to go beyond risk mitigation. By strengthening internal collaboration and supplier relationships, procurement can also help accelerate development timelines.
Working closely with suppliers to streamline processes and remove inefficiencies can support faster progression through development stages. Earlier market entry extends periods of exclusivity while competitors catch up, directly improving commercial outcomes. At the same time, patients benefit from quicker access to innovative treatments.
This dual impact, protecting value while actively creating it, underscores the strategic importance of procurement leadership during periods of uncertainty.
As the UK pharmaceutical industry navigates the impact of pharmaceutical tariffs and wider geopolitical pressures, CPOs have a clear opportunity to step up. Leaders who equip their teams to manage supplier costs, safeguard brand reputation, and collaborate effectively across the organisation can deliver meaningful value. In doing so, they help protect the business today while strengthening its position for the future.